OptiNose, Inc. (OPTN) News
Filter OPTN News Items
OPTN News Results
|Loading, please wait...|
OPTN News Highlights
- For OPTN, its 30 day story count is now at 2.
- Over the past 16 days, the trend for OPTN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about OPTN are REGN, BEAT and BMO.
Latest OPTN News From Around the Web
Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), BellRing Brands (BRBR) and Optinose (OPTN)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), BellRing Brands (BRBR – Research Report) and Optinose (OPTN – Research Report) with bullish sentiments. Regeneron (REGN) BMO Capital analyst Evan Seigerman reiterated a Buy rating on Regeneron today and set a price target of $780.00. The company's shares closed last Friday at $622.96. According to TipRanks.
Here is how NuCana PLC Sponsored ADR (NCNA) and OptiNose (OPTN) have performed compared to their sector so far this year.
Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors. Eric and Kyle currently serve as Partners at MVM Partners LLP (MVM), a growth equity firm that has invested in innovative, high growth healthcare businesses since 1997. With teams in Boston and London, MVM has a succ
OptiNose (NASDAQ:OPTN) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or  The post OptiNose (NASDAQ:OPTN) Downgraded by Zacks Investment Research appeared first on ETF Daily News .
State Street Corp lessened its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN) by 83.7% during the second quarter, Holdings Channel.com reports. The firm owned 93,995 shares of the companys stock after selling 483,816 shares during the quarter. State Street Corps holdings in OptiNose were worth $292,000 at the end of the most recent quarter. Several 
Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN) from a hold rating to a buy rating in a report issued on Saturday, Zacks.com reports. They currently have $1.75 price target on the stock. According to Zacks, OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated 
Northern Trust Corp cut its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN) by 81.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 67,965 shares of the companys stock after selling 307,422 shares during the period. Northern Trust Corp owned approximately 0.13% of OptiNose worth  The post OptiNose, Inc. (NASDAQ:OPTN) Shares Sold by Northern Trust Corp appeared first on ETF Daily News .